• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

FDA approves IXINITY for treatment of hemophilia B in patients 12 years and under

News
Article

IXINITY is now approved to treat all patients with the hemophilia B to help control bleeding episodes, as well as reduce the frequency of them.

FDA approves IXINITY sBLA for treatment of hemophilia B in patients 12 years and under © calin - stock.adobe.com

FDA approves IXINITY sBLA for treatment of hemophilia B in patients 12 years and under © calin - stock.adobe.com

The FDA has approved a supplemental Biologics License Application (sBLA) for IXINITY (coagulation factor IX [recombinant]; Medexus Pharmaceuticals) for the on-demand, prophylactic, and perioperative treatment of pediatric patients 12 years and under with hemophilia B.

According to Medexus, IXINITY is an intravenous recombinant factor IX therapeutic which was previously approved for use in patients 12 years and up with hemophilia B.

However, following this approval, IXINITY is now approved to treat all patients with hemophilia B to help control bleeding episodes, as well as reduce the frequency of them.

Hemophilia B is a hereditary blood disorder that is a result of a deficiency of clotting factor IX in the blood, according to a company press release.

Symptoms may include trauma-induced or spontaneous bleeding into muscles, soft tissues, and joints, which can lead to joint damage, severe arthritis, and mobility reduction.

“IXINITY effectively prevented and controlled bleeding episodes in the phase 3/4 pediatric study,” said one of the study’s principal investigators, Johnny Mahlangu, BSc, MBBCh, MMed, FCPath.

He added, “The study supported the efficacy and safety of IXINITY in pediatric patients, and the pharmacokinetics and safety profile were consistent with those observed in adults, although dose adjustment may be needed in pediatric patients. The results thus provide further validation of the clinical utility of IXINITY as a treatment for all people living with hemophilia B.”

Reference:

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients. Market Screener. March 27, 2024. Accessed March 28, 2024. https://www.marketscreener.com/quote/stock/MEDEXUS-PHARMACEUTICALS-I-49601873/news/FDA-Approves-Medexus-s-Supplemental-Biologics-License-Application-for-IXINITY-to-Treat-Hemophilia-B-46299205

Related Videos
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Tina Tan, MD
© 2024 MJH Life Sciences

All rights reserved.